Lazanda in Cancer Patients Receiving Palliative Radiation
Status:
Terminated
Trial end date:
2018-03-09
Target enrollment:
Participant gender:
Summary
Advanced cancer patients often require palliative (pain relieving) radiotherapy to treat
cancer-related symptoms. The delivery of radiation requires patients to lie still on a hard
flat surface, which can result in significant acute (intense) pain and/or breakthrough cancer
pain (sudden sharp or stabbing pain), especially when painful bone metastases are present.
The current care for most cancer patients receiving radiation is to take an oral (by mouth)
opioid medication before the radiation treatment. The pain relieving effects of these
medications can take about one hour and can last for 3 to 6 hours, which does not follow the
time course of when breakthrough cancer pain occurs.
Lazanda is a pain medication delivered via an intranasal route and is already approved by the
U.S. Food and Drug Administration (FDA) for the management of breakthrough cancer pain for
patients who are already receiving opioids and who can tolerate opioids for the treatment of
cancer pain. Lazanda is fast-acting and convenient for patients to take. The purpose of this
study is to assess the change in pain intensity during palliative radiotherapy following
study treatment with Lazanda. This study will also explore the impact of the study treatment
on the efficiency in delivering the radiation therapy